安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Recurrent Glioblastoma: A Review of the Treatment Options
Glioblastoma is the most common malignant brain tumor associated with a poor prognosis, with a median survival of 14 months Despite initial treatment with surgery, radiotherapy, and chemotherapy, recurrence is the usual situation
- Recurrence analysis of glioblastoma cases based on distance and dose . . .
The aim of this study was to examine the recurrence pattern of GBM following modern radiochemotherapy according to EORTC guidelines and provide dose and distance information for the choice of optimal target volume margins
- Facts Statistics – Henry A. Swann, Jr. Foundation
GBM accounts for 50 1 percent of all primary malignant brain tumors It is estimated that more than 10,000 individuals in the United States will succumb to glioblastoma every year The five-year survival rate for glioblastoma patients is only 6 9 percent
- Glioblastoma Multiforme - StatPearls - NCBI Bookshelf
Glioblastoma multiforme (GBM) is the most malignant and pervasive subtype of glioma and is the most common primary brain tumor in adults It remains an incurable disease with a median survival of 15 months and has been classified into wild-type and mutant isocitrate dehydrogenase (IDH) subtypes
- “Comprehensive Analysis of Factors Influencing Recurrence and . . . - MDPI
Statistical analyses were performed to develop a prognostic model for glioblastoma recurrence and estimate survival rates Among the patients, 65 4% had no recurrence, with a mean age of 63 years No gender or BMI differences were observed, but ages <60 years were associated with recurrence
- Recurrence Pattern Analysis of Primary Glioblastoma
Local, distant, and combined tumor recurrence patterns were observed in 77 (79 3%), 10 (10 3%), and 10 patients (10 3%) Median progression-free survival of all patients was 8 months; median overall survival was 20 months
- Overall survival in patients with recurrent glioblastomas with . . .
Most GBM recurs in 6 to 9 months and the median OS since recurrence is 3 to 9 months Despite advancements in clinical trials, there is no uniform standard of care (SOC) for recurrent GBM
- Management of glioblastoma after recurrence: A changing paradigm
In this review we intend to review available investigations for the diagnosis and treatment modalities with meaningful impact on survival and derive a possible therapeutic algorithm for patients with recurrent GBM We searched the PubMed for literature of recurrent glioblastoma
|
|
|